Messenger RNA-based drug (mRNA-based drug)

Messenger RNA-based drugs are a therapeutic strategy in which synthetic mRNA molecules are delivered into patient cells to produce therapeutic proteins, antigens, or other biologically active molecules. Unlike small-molecule drugs or protein therapeutics, mRNA drugs function by leveraging the patient’s own cellular machinery for protein synthesis. Their applications range from vaccines (e.g., COVID-19 spike protein mRNA vaccines) to protein replacement for genetic disorders and cancer immunotherapies. These drugs do not alter DNA and are designed to be transiently expressed. Key technical challenges involve mRNA stability, efficient cellular delivery (often using lipid nanoparticles), and managing immune responses to both the mRNA and its delivery systems. mRNA-based drug platforms have revolutionized vaccine development and show promise for rapid, scalable treatments for a wide range of diseases[2][3][4][5][6][7].

Other names

mRNA drugsmRNA therapeuticsmRNA vaccinesMessenger RNA therapeuticsMessenger RNA vaccines

Delivery of exogenous mRNA into patient cells; cellular translation of mRNA produces the encoded protein. For vaccines: mRNA encodes antigens; cellular translation, antigen presentation, induction of adaptive immune response (antibodies, T cells). For protein replacement: mRNA encodes therapeutic protein missing or deficient in disease. For immunomodulation: mRNA encodes immunoregulatory molecules to reprogram immune responses (cytokines, tolerization antigens, etc.).